Compare ResMed Inc. (RMD) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Wheaton Precious Metals Corp — how do they compare? ResMed Inc. trades at $194.03 (market cap $28.81B), while Wheaton Precious Metals Corp trades at $110.88 (market cap $46.54B). The key difference: Wheaton Precious Metals Corp is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| RMD | WPM | |
|---|---|---|
Market Cap | $28.81B | $46.54B |
Sector | Health | Basic Materials |
52-Week High | $293.73 | $165.72 |
52-Week Low | $182.82 | $91.00 |
Enterprise Value | $27.99B | $44.39B |
Dividend Yield | 1.21% | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Wheaton Precious Metals (WPM) trades at $109.96, up 5.55% today, with a bearish technical signal but strong fundamentals. The company reported record revenue of $2.31B in 2025, net income of $1.47B, and has beaten earnings estimates for three consecutive quarters. Operating cash flow surged to $1.90B in 2025, supporting a positive outlook.
WPM offers growth potential with an 80% analyst buy rating and a consensus price target of $161.75, implying significant upside. Risks include exposure to precious metal price volatility and a high P/E ratio of 26.14. The stock's current discount to target presents a buying opportunity for long-term investors, contingent on stable metal prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
